Navigation Links
New Data Focuses on Abuse of Stimulant Medication

New Data Suggests Less Abuse-Related Effects For OROS(r) Methylphenidate

Two New Studies Highlight Potential Benefit of Unique OROS(r) Formulation

SAN DIEGO, CA, May 22, 2007 - Stimulant drug abuse remains an ongoing concern for parents and physicians who prescribe medications to treat Attention Deficit Hyperactivity Disorder (ADHD). Data presented on Tuesday at the 160th Annual Meeting of the American Psychiatric Association highlighted findings that long-acting OROS(r) methylphenidate had fewer reports of abuse and lower abuse-related effects compared with other long- and short-term stimulant medications for ADHD.

The unique, long-acting OROS(r) methylphenidate formulation initially releases the drug, followed by a more gradual release of the remaining dose in an ascending pattern, compared with an immediate-release, or short-acting, methylphenidate formulation. The data presented on Tuesday from two sources - a national review of emergency department visits and a pharmacokinetic/pharmacodynamic study - highlights a possible benefit related to reduced abuse potential that may be associated with the OROS(r) methylphenidate formulation.

"Although methylphenidate is proven to be an effective treatment for ADHD, some physicians may have concerns about the drug due to its abuse potential," said John J. Coleman, Ph.D., president of Prescription Drug Research Center. "Most patients take prescription medications responsibly, however, recent reviews still show that illicit stimulant use among adolescents in the United States remains a concern for physicians, parents and the general public."

About The Data

Drug Abuse Warning Network (DAWN) Review of Drug-Related Emergency Department Visits Among ADHD Treatments (APA Poster Board NR526)

DAWN data, a national health surveillance system that monitors drug-related emergency department visits, was used to examine emergency de
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Annual Meeting of the Consortium of Multiple Sclerosis Centers Focuses on the Challenges of Care and Research in Multiple Sclerosis
2. Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse
3. Study Suggests Strattera Improved ADHD Symptoms in Patients With Comorbid Alcohol Abuse
4. New Data Suggests Less Abuse-Related Effects For OROS Methylphenidate
5. Alpharma Presents Positive Pharmacokinetic Study Results of Its Investigational Abuse-Deterrent, Extended-Release Opioid
6. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
7. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
8. Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial
9. FDA Proposes New Warnings About Suicidal Thinking, Behavior in Young Adults Who Take Antidepressant Medications
10. Survey: Migraine Patients Taking Potentially Addictive Barbiturate or Opioid Medications Not Approved by FDA as Migraine Treatments
11. Drug for Treatment of Heart Failure Does Not Improve Survival, Compared to More Widely-used Medication
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Data Focuses Abuse Stimulant Medication
(Date:5/4/2015)... May 4, 2015 RadiologyAuction will have their first ... and product demonstrations at the end of the auction ... as Kodak and Fuji Cr,s, Agfa and Sony, printers ... first event. Various imaging equipment will be available at ... After years of buying and selling imaging equipment, ...
(Date:5/4/2015)... 2015 Rogne Bioscience, a privately-held biotechnology company ... preclinical and mechanism of action data will be presented ... Dermatology (SID) Annual Meeting being held May 6-9, 2015 ... . Logo - http://photos.prnewswire.com/prnh/20150501/213318LOGO ... a novel, low MW (<1700 daltons) peptide as a ...
(Date:5/4/2015)... -- Bayer HealthCare (Bayer) has entered into an exclusive ... ) on ISIS-FXI Rx, an antisense investigational drug ... the agreement Bayer will further develop and commercialize ISIS-FXI ... As part of the clinical development program, Bayer plans ... in an appropriate patient community. "Bayer is ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
... SINGAPORE , UPPSALA, Sweden and CANTON, Mass. , ... that the US Food and Drug Administration (FDA) has given the ... Mesh, for use in reinforcement of soft tissues where weakness exists. ... synthetic matrix, knitted from two different resorbable fibers that degrade at ...
... SAN FRANCISCO, Calif. , Feb. 5 Poniard Pharmaceuticals, Inc. ... today announced that Ronald Martell , chief executive officer, will provide ... on Tuesday, February 9, 2010 at 1:00 p.m. Eastern ... . , A live audio webcast of the corporate overview will be ...
Cached Medicine Technology:Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - World's 1st Long-Term Resorbable Synthetic Mesh 2Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - World's 1st Long-Term Resorbable Synthetic Mesh 3Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference 2
(Date:5/4/2015)... 05, 2015 The National ... Irene Taylor , Volunteer Executive Director of National ... inductee into its VIP Woman of the Year ... for leadership in business. NAPW is the nation's ... more than 700,000 members and over 200 Local ...
(Date:5/4/2015)... The National Association of Professional Women ... a 2015-2016 inductee into the NAPW VIP Woman of ... distinction for leadership in healthcare. NAPW is the nation's ... than 700,000 members and over 200 operating Local Chapters. ... group of professional women,” says NAPW President Star Jones. ...
(Date:5/4/2015)... (PRWEB) May 05, 2015 The ... Shirley Weis as a 2015-2016 inductee into its ... with this prestigious distinction for leadership in healthcare. NAPW ... women, boasting more than 700,000 members and over 200 ... with this important honor,” says NAPW President Star Jones. ...
(Date:5/4/2015)... IOWA (PRWEB) May 04, 2015 The ... appointed Gregs G. Thomopulos, P.E., Chairman of Stanley ... (ISI) board of directors for a three-year term. ... Association (APWA) and the American Society of Civil Engineers ... a sustainability rating system for civil infrastructure called Envision. ...
(Date:5/4/2015)... 04, 2015 HHT is a rare ... While it can have seemingly mild symptoms like ... events. Hereditary Hemorrhagic Telangiectasia (HHT) is a hereditary ... lack normal capillary connections between an artery and a ... severe nosebleeds, but may also be present in the ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Irene Taylor into its 2015-2016 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Jennifer Yates Doherty, Owner of Palmetto Rehabilitation Services, LLC, into its 2015 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Shirley Weis, President at Weis Associates, LLC, into its 2015-2016 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Shirley Weis, President at Weis Associates, LLC, into its 2015-2016 VIP Woman of the Year Circle 3Health News:Thomopulos Appointed to Institute for Sustainable Infrastructure Board 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 3
... May 20 (ZealousPR) Award-winning Vanity,Fair writer and hospice ... tri-weekly "advice column on dying well,", http://www.TheCheckoutLine.org -- ... who care about them, today. Every Monday, Wednesday and,Friday, ... questions,and offering advice for anyone needing help on the ...
... of developing asthma and allergy because of different conditions ... from the Isle of Wight in the United Kingdom, ... 2008 International Conference in Toronto on Wednesday, May 21., ... asthma and allergy in first-born children is the result ...
... Allows Patients the Ability to Share their Prescription ... Longs Drug,Stores Corporation (NYSE: LDG ) announced ... a platform for sharing of information between,patients and ... of the first,pharmacies to provide their customers with ...
... CHICAGO (May 19, 2008) New research published in ... long-term survival and liver rejection rates are equivalent for ... other races. The study also suggests that although other ... influence long-term survival, race does not. , ...
... ... Leadership, CHICAGO, May 19 Ventas, Inc. (NYSE: VTR ... declared,a regular quarterly dividend of $0.5125 per share, payable in cash ... The dividend is the,second quarterly installment of the Company,s 2008 annual ...
... procedure performed by Dr. Robert S. Bray, Jr. of ... D.I.S.C. Spine ... Roach is living,her dream after successfully qualifying for the 2008 ... one of the country,s preeminent,neurological spinal surgeons specializing in micro ...
Cached Medicine News:Health News:Award Winning Vanity Fair Contributing Editor Judy Bachrach Launches 'TheCheckoutLine.org - An Advice Column on Dying Well' 2Health News:First-born babies' higher asthma and allergy rates due to pregnancy conditions 2Health News:Longs Drugs Partners With Google on the Launch of Google Health 2Health News:Study concludes no racial disparities in long-term outcomes in recipients of liver transplants 2Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 2Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 3Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 4Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 5Health News:Successful Back Surgery Propels Olympic Weightlifting Hopeful Melanie Roach to Realize Her Dreams Of Participating in the 2008 Beijing Olympics 2
Straight heavy shafts with delicate 7 mm tying platform. Sharp pointed tips for removing fine sutures. Wide serrated handle with polished finish. Overall length 4.1 inches....
Angled 45 degree shafts with 10.5 mm tying and 1 mm of tip crisscross serrated. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.2 inches....
Curved, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Titanium. Straight shafts with 6.5 mm tying platform. Round knurled handle with dull finish. Overall length 4.4 inches....
Medicine Products: